CareLit Fachartikel
A single infusion of Zoledronic Acid after terminating treatment with Denosumab prevents rebound-fractures and rapid loss of bone mineral densitiy in most, but not all patients tr…
T Lehmann, J Everts · Osteologie · 2019 · Heft 01
Dokument
1196895
CareLit-ID
Jahr
2019
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
A single infusion of Zoledronic Acid after terminating treatment with Denosumab prevents rebound-fractures and rapid loss of bone mineral densitiy in most, but not all patients treated for Osteoporosis
Schlagworte
Denosumab
After
Osteologie